Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 50 entries
View as:

Bone Pain Score Validation Initiative

Phase: N/A Priority: Normal
NCT ID: NCT02293642 Org: User:
Start: 12/31/14 End: 06/30/16 Due: 06/30/17

Liver Cancer Registry Platform

Phase: N/A Priority: Normal
NCT ID: NCT04510740 Org: User:
Start: 08/09/20 End: 12/31/27 Due: 12/31/28

Tumour Registry Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01351584 Org: User:
Start: 02/28/07 End: 12/31/21 Due: 12/31/22

Tumor Registry of Advanced Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00610012 Org: User:
Start: 12/31/07 End: 05/15/20 Due: 05/15/21

Myeloma Registry Platform (MYRIAM)

Phase: N/A Priority: Normal
NCT ID: NCT03308474 Org: User:
Start: 09/25/17 End: 12/31/28 Due: 12/31/29

Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT03911219 Org: User:
Start: 07/10/19 End: 07/01/21 Due: 07/01/22

Patient Reported Outcomes Registry in Patient With Cancer Cachexia

Phase: N/A Priority: Normal
NCT ID: NCT02983500 Org: User:
Start: 08/28/16 End: 07/24/19 Due: 07/24/20

Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly

Phase: N/A Priority: Normal
NCT ID: NCT06743035 Org: User:
Start: 12/03/24 End: 07/31/29 Due: 07/31/30

Non-interventional Study With Nab-Paclitaxel (Abraxane®)

Phase: N/A Priority: Normal
NCT ID: NCT01689610 Org: User:
Start: 04/30/12 End: 03/31/16 Due: 03/31/17

Registry Platform Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04867525 Org: User:
Start: 05/01/21 End: 04/30/26 Due: 04/30/27

Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)

Phase: N/A Priority: Normal
NCT ID: NCT01266837 Org: User:
Start: 03/31/11 End: 10/31/17 Due: 10/31/18

Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00868634 Org: User:
Start: 02/28/09 End: 10/31/15 Due: 10/31/16

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab

Phase: N/A Priority: Normal
NCT ID: NCT02248571 Org: User:
Start: 08/31/14 End: 09/30/17 Due: 09/30/18

Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT02799862 Org: User:
Start: 08/29/16 End: 06/06/21 Due: 06/06/22

Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.

Phase: N/A Priority: Normal
NCT ID: NCT05253911 Org: User:
Start: 05/21/22 End: 05/31/27 Due: 05/31/28

Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)

Phase: N/A Priority: Normal
NCT ID: NCT05517265 Org: User:
Start: 10/12/22 End: 03/31/26 Due: 03/31/27

Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study

Phase: N/A Priority: Normal
NCT ID: NCT06607302 Org: User:
Start: 10/08/24 End: 12/31/27 Due: 12/31/28

Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

Phase: N/A Priority: Normal
NCT ID: NCT02894398 Org: User:
Start: 09/06/16 End: 02/15/23 Due: 02/15/24

Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)

Phase: N/A Priority: Normal
NCT ID: NCT03043950 Org: User:
Start: 01/25/17 End: 01/17/24 Due: 01/17/25

Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT05954780 Org: User:
Start: 06/28/23 End: 09/15/26 Due: 09/15/27

Breast Cancer Registry Platform

Phase: N/A Priority: Normal
NCT ID: NCT03417115 Org: User:
Start: 12/22/17 End: 04/30/29 Due: 04/30/30

Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line

Phase: N/A Priority: Normal
NCT ID: NCT03462251 Org: User:
Start: 05/24/18 End: 11/30/22 Due: 11/30/23

Epidemiological EMESIS-Registry

Phase: N/A Priority: Normal
NCT ID: NCT00911222 Org: User:
Start: 10/31/08 End: 08/31/09 Due: 08/31/10

Tumor Registry of Lymphatic Neoplasia

Phase: N/A Priority: Normal
NCT ID: NCT00889798 Org: User:
Start: 04/30/09 End: 08/31/19 Due: 08/31/20

Non-interventional Study With Pomalidomide (Imnovid®)

Phase: N/A Priority: Normal
NCT ID: NCT02075996 Org: User:
Start: 02/11/14 End: 02/04/21 Due: 02/04/22